p.96 抽出テキスト

markers of ventricular arrhythmogenesis in patients referred to ambulatory 24-hour ECG recording. Int J Cardiol 2012; 160: 175-180. PMID: 21549435 654. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year followup of 21 patients. Circulation 1995; 91: 1512- 1519. PMID: 7867192 655. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70. PMID: 12482795 656. Lieve KV, van der Werf C, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia. Circ J 2016; 80: 1285- 1291. PMID: 27180891 657. Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: Analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol 2015; 8: 633-642. PMID: 25713214 658. Napolitano C, Priori SG, Bloise R. Catecholaminergic polymorphic ventricular tachycardia. In: GeneReviews

® [Internet]. University of Washington, 2004. PMID: 20301466 659. Tester DJ, Dura M, Carturan E, et al. A mechanism for sudden infant death syndrome (SIDS): Stress-induced leak via ryanodine receptors. Heart Rhythm 2 0 0 7 ; 4 : 7 3 3 - 7 3 9 . PMID: 17556193 660. Leinonen JT, Crotti L, Djupsjöbacka A, et al. The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia? Int J Cardiol 2018; 250: 139-145. PMID: 29032884 661. Ozawa J, Ohno S, Fujii Y, et al. Differential diagnosis between catecholaminergic polymorphic ventricular tachycardia and long QT syndrome Type 1: Modified Schwartz score. Circ J 2018; 82: 2269-2276. PMID: 29925740 662. van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: Disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012; 5: 748-756. PMID: 22787013 663. Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR 2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005; 42: 863- 870. PMID: 16272262 664. Butters A, Isbister JC, Medi C, et al. Epidemiology and clinical characteristics of atrial fibrillation in patients with inherited heart diseases. J Cardiovasc Electrophysiol 2020; 31: 465-473. PMID: 31930598 665. Sumitomo N, Sakurada H, Taniguchi K, et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 2007; 71: 1606-1609. PMID: 17895559 666. Imberti JF, Underwood K, Mazzanti A, et al. Clinical challenges in catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ 2016; 25: 777-783. PMID: 26948768 667. Blich M, Marai I, Suleiman M, et al. Electrocardiographic comparison of ventricular premature complexes during exercise test in patients with CPVT and healthy subjects. Pacing Clin Electrophysiol 2015; 38: 398-402. PMID: 25627675 668. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q 42-q 43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34: 2035-2042. PMID: 10588221 669. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69- 74. PMID: 12093772 670. Hayashi M, Denjoy I, Hayashi M, et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace 2012; 14: 1344-1351. PMID: 22383456 671. Inoue YY, Aiba T, Kawata H, et al. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. Europace 2018; 20: 1675- 1682. PMID: 29309601 672. Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012; 23: 194-199. PMID: 21954897 673. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca

2+ handling and arrhythmogenesis. Circ Res 2011; 108: 871- 883. PMID: 21454795 674. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: Clinical features and assignment of the disease gene to chromosome 1p 13- 21. Circulation 2001; 103: 2822- 2827. PMID: 11401939 675. Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet 2012; 21: 2759-2767. PMID: 22422768 676. Ng K, Titus EW, Lieve KV, et al. An international multicenter evaluation of inheritance patterns, arrhythmic risks, and underlying mechanisms of CASQ 2-catecholaminergic polymorphic ventricular tachycardia. Circulation 2020; 142: 932- 947. PMID: 32693635 677. Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res 2017; 121: 784-802. PMID: 28912183 678. Peters S. Advances in the diagnostic management of arrhythmogenic right ventricular dysplasia-cardiomyopathy. Int J Cardiol 2006; 113: 4-11. PMID: 16737750 679. Corrado D, Basso C. Arrhythmogenic left ventricular cardiomyopathy. Heart 2021 Jul 13. doi: 10.1136/heartjnl-2020-316944 PMID: 34257076 680. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019; 16: e301-e372. PMID: 31078652 681.Corrado D, Perazzolo Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol 2020; 319: 106-114. PMID: 32561223 682. Corrado D, van Tintelen PJ, McKenna WJ, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020; 41: 1414-1429. PMID: 31637441 683. Imamura T, Sumitomo N, Muraji S, et al. Impact of the T-wave characteristics on distinguishing arrhythmogenic right ventricular cardiomyopathy from healthy children. Int J Cardiol 2021; 323: 168-174. PMID: 32877757 684. Wada Y, Ohno S, Aiba T, et al. Unique genetic background and outcome of non-Caucasian Japanese probands with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Mol Genet Genomic Med 2017; 5: 639-651. PMID: 29178656 685. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013; 62: 1290- 1297. PMID: 23871885 686. Te Riele ASJM, James CA, Sawant AC, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy in the pediatric population: Clinical characterization and comparison with adultonset disease. JACC Clin Electrophysiol 2015; 1: 551- 560. PMID: 29759408 687. Ruwald AC, Marcus F, Estes NA 3rd, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2015; 36: 1735-1743. PMID: 25896080 688. Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail 2014; 16: 1337-1344. PMID: 25319773 689. Sawant AC, Bhonsale A, te Riele AS, et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc 2014; 3: e 001471. PMID: 25516436 690. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: A scientific statement from the American Heart Association and American College of Cardiology. Circulation 2015; 132: e273-e280. PMID: 26621644 691. Denis A, Sacher F, Derval N, et al. Arrhythmogenic response to isoproterenol testing vs. exercise testing in arrhythmogenic right ventricular cardiomyopathy patients. Europace 2018; 20: f30-f36. PMID: 29401235